Pegvaliase (2) – Palynziq®

Phenylketonuria; 12 to < 16 years

Characteristics

Start date 01.08.2026
Resolution 21.01.2027 – active procedure
INN Pegvaliase
Brand name Palynziq®
Pharm. company BioMarin Deutschland GmbH
G-BA Procedure ID D-1366
Therapeutic area Metabolic diseases Orphan
Reason for procedure New therapeutic indication

Associated procedures

Pegvaliase (2) Palynziq® BioMarin Deutschland GmbH Metabolic diseases Phenylketonuria; 12 to < 16 years n.d. active procedure Orphan
Pegvaliase (1) Palynziq® BioMarin International Limited Metabolic diseases Phenylketonuria 435 100% Hint for non-quantifiable additional benefit Orphan


<< List of all resolutions